文献速递甲状腺疾病

低风险分化型甲状腺癌的当前争议:在过度诊断时代减少过度治疗

Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

本文是一篇小型综述,概述低风险分化型甲状腺癌从诊断到治疗及随访全过程中的争议与困难决策,涵盖过度诊断、主动监测与手术的选择、手术范围、放射性碘治疗、促甲状腺激素抑制及术后监测等方面。文章指出过去十年相关推荐已发生重大变化,临床医生与患者需个体化权衡治疗范围,在证据均衡领域可借助以患者为中心结局的数据辅助决策。

要点

  • 低风险分化型甲状腺癌过度诊断问题突出,但真实发病率亦有所上升。
  • 治疗选择范围从主动监测小肿瘤到全甲状腺切除后选择性放射性碘治疗。
  • 长期监测频率与持续时间推荐差异较大,需个体化决策。

核心结论

  • 临床医生与患者必须对每个病例采取个体化且细致的方式,以选择适合个体的治疗范围。
  • 在证据均衡的领域,关于以患者为中心结局的数据可能有助于指导决策。

研究设计与样本

  • 本文为小型综述,概述低风险分化型甲状腺癌各阶段管理中的争议与困难决策。

主要发现

  • 过去十年中,关于分化型甲状腺癌诊断、低风险患者治疗范围及治疗后随访强度的推荐均已发生重大变化。
  • 过度诊断仍是一个问题,但发病率也确实有所增加。
  • 治疗选项范围从对小肿瘤的主动监测到全甲状腺切除后选择性放射性碘治疗。
  • 长期监测频率与持续时间的推荐同样差异较大。

临床怎么用

  • 原文未据此给出推荐,仅提出临床医生与患者应个体化选择治疗范围。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Low-risk differentiated thyroid cancer (DTC) is overdiagnosed, but true incidence has increased as well. Owing to its excellent prognosis with low morbidity and mortality, balancing treatment risks with risks of disease progression can be challenging, leading to several areas of controversy. EVIDENCE ACQUISITION: This mini-review is an overview of controversies and difficult decisions around the management of all stages of low-risk DTC, from diagnosis through treatment and follow-up. In particular, overdiagnosis, active surveillance vs surgery, extent of surgery, radioactive iodine (RAI) treatment, thyrotropin suppression, and postoperative surveillance are discussed. EVIDENCE SYNTHESIS: Recommendations regarding the diagnosis of DTC, the extent of treatment for low-risk DTC patients, and the intensity of posttreatment follow-up have all changed substantially in the past decade. While overdiagnosis remains a problem, there has been a true increase in incidence as well. Treatment options range from active surveillance of small tumors to total thyroidectomy followed by RAI in select cases. Recommendations for long-term surveillance frequency and duration are similarly broad. CONCLUSION: Clinicians and patients must approach each case in a personalized and nuanced fashion to select the appropriate extent of treatment on an individual basis. In areas of evidential equipoise, data regarding patient-centered outcomes may help guide decision-making.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ullmann TM, Papaleontiou M, Sosa JA, et al. Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis. J Clin Endocrinol Metab. 2023. PMID: 36327392. doi:10.1210/clinem/dgac646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。